Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 9/20 | 0.44 |
| ▸ | CHUK | O15111 | 8/20 | 0.44 |
| ▸ | CDK2 | P24941 | 2/20 | 0.36 |
| ▸ | CDK4 | P11802 | 1/20 | 0.36 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.36 |
| ▸ | CDK1 | P06493 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | IGF1R | P08069 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | SYK | P43405 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3299907 | 0.93 | RAB9A (0.40) | CDK2CDK4CCNE1MAPTSMN1; SMN2 | |
| SCHEMBL3302160 | 0.86 | IKBKB (0.47) | IKBKBCHUKCDK2CDK4CCNE1 | |
| SCHEMBL3299898 | 0.79 | MAPT (0.43) | IKBKBCHUKCDK2CDK4CCNE1 | |
| SCHEMBL3300483 | 0.75 | IKBKB (0.43) | IKBKBCHUKCDK2CDK4CCNE1 | |
| SCHEMBL13392487 | 0.75 | MAPT (0.51) | IKBKBCHUKCDK2CCNE1MAPT | |
| SCHEMBL13392087 | 0.75 | IKBKB (0.46) | IKBKBCHUKCDK2CDK4CCNE1 | |
| SCHEMBL3303279 | 0.74 | IKBKB (0.51) | IKBKBCHUKCDK2CDK4CCNE1 | |
| SCHEMBL3306513 | 0.74 | IKBKB (0.51) | IKBKBCHUKCDK2CDK4CCNE1 | |
| SCHEMBL3980488 | 0.74 | IKBKB (0.43) | IKBKBCHUKCDK2CDK4CCNE1 | |
| SCHEMBL13392085 | 0.74 | RAB9A (0.47) | IKBKBCHUKCDK2CCNE1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093668-A1 | N,N'-2,4-DIANILINOPYRIMIDINE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS ESSENTIALLY AS IKK INHIBITORS | SANOFI-AVENTIS (FR) | 2010-04-15 | — | — | US | disclosed |
| EP-2118092-A1 | NEW N, N'- 2,4-DIANILINOPYRIMIDINE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS ESSENTIALLY AS IKK INHIBITORS | Sanofi-Aventis (FR) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008099073-A1 | N, N' -2, 4-DIANILINOPYRIMIDINES PREPARATION AND USE THEREOF AS IKK INHIBITORS PREPARATION AND TEH PHARMACUETICAL COMPOSITIONS THEREOF | SANOFI-AVENTIS (FR) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093668-A1 | N,N'-2,4-DIANILINOPYRIMIDINE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS ESSENTIALLY AS IKK INHIBITORS | CHUK, IKBKB, IKBKE | IKBKB 2/4885CHUK 1/4885CDK2 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.